Predictors and outcome of patients with acute respiratory distress syndrome caused by miliary tuberculosis: a retrospective study in Chongqing, China

Wang Deng1, Min Yu1, Hilary Ma2, Liang An Hu3, Gang Chen4, Yong Wang5, Jia Deng1, Changyi Li1, Jin Tong1 and Dao Xin Wang1*

Abstract

Background: Miliary tuberculosis (TB) is an uncommon cause of acute respiratory distress syndrome (ARDS) with a high mortality. The aim of the present study was to evaluate the clinical characteristics, predictors and outcome of patients with ARDS caused by miliary TB.

Methods: A retrospective study was conducted among patients with a diagnosis of ARDS with miliary TB in four hospitals from 2006 to 2010. Medical records and laboratory examinations of these patients were taken during the first 24 h of admission.

Results: Eighty-five patients with miliary TB developed ARDS, 45 of whom survived (52.9%). The median age was 36.6 ± 12.5 years with 38 males (44.7%). Diabetes mellitus (DM) was the most common underlying disease (18.8%). ICU mortality was 47.1%. The time from admission to anti-tuberculosis therapy was 4.5 ± 2.0 days. Mean duration of mechanical ventilation was 8.5 ± 3.0 days in all patients. Duration of time to diagnosis, time from diagnosis to mechanical ventilation, and time to anti-tuberculosis therapy were significantly shorter in survivors than those in non-survivors. Diabetes mellitus (OR 5.431, 95%CI 1.471-20.049; P = 0.005), ALT (70-100U/L, OR 10.029, 95%CI 2.764-36.389; P = 0.001), AST (>94U/L, OR 8.034, 95%CI 2.200-29.341; P = 0.002), D-dimer (>1.6mg/L, OR 3.167, 95%CI 0.896-11.187; P = 0.042), hemoglobin (<90g/L, OR 4.728, 95%CI 1.376-16.255; P = 0.001), albumin (<25g/L, OR 4.728, 95%CI 1.376-16.255; P = 0.001) were independent predictors of ARDS development in the setting of miliary TB.

Conclusions: Accurate diagnosis, early initiation of anti-tuberculosis therapy and mechanical ventilation are important for the outcome of patients with ARDS caused by miliary TB. DM, ALT, AST, D-dimer, hemoglobin, and albumin are independent predictors of ARDS development in patients with miliary TB.

Keywords: Acute respiratory distress syndrome, Miliary tuberculosis, Predictors, China

Background

Tuberculosis (TB) remains a major and global health disease[1,2]. Recent studies have shown the link between acute respiratory distress syndrome (ARDS) and pulmonary TB[3,4]. Pulmonary TB complicated by ARDS is often found in the setting of miliary TB[3-6]. Most reports on ARDS caused by miliary TB are small numbers of patients in the case reports. Compared with miliary TB alone, miliary TB with ARDS portends a higher mortality of 33-90% [7-9]. Duration of miliary TB beyond 20 days tends to markedly increase the risk of ARDS [10]. It is very important for recognition of ARDS caused by miliary TB.

Despite being a well-documented entity, miliary TB complicated by ARDS remains a challenging diagnosis due to its variable clinical manifestations and low morbidity. Some predictors such as AST, and ALT[4,10] in miliary TB with ARDS have drawn our attention. Numerous case reports have mentioned that TB with ARDS is more...
common than TB complicated by anemia[4,11] and hypoproteinemia[6,11]. Thus, identifying the predictors of miliary TB associated with ARDS can play an important role in diagnosis and therapy. The aim of the present study was to determine the predictors and their impact on outcome based on a retrospective analysis of patients with ARDS caused by miliary TB in four hospitals of Chongqing in China, with the hope that this will contribute to a better understanding and improved management of the disease.

Methods
Study design
Over a 5-year period (2006.03.31-2010.03.31), 16238 patients were admitted with a diagnosis of pulmonary TB in the respiratory departments of Second Affiliated Hospital of Chongqing Medical University, First Affiliated Hospital of Chongqing Medical University, Chest Hospital and Pulmonary Hospital in Chongqing, China. Of these, 471 patients were diagnosed with miliary TB. Five patients were excluded for further analysis due to transfer to another hospital within 2 days. Of the remaining 466 patients, 85 patients developed ARDS were admitted to the ICU during the study period. The patients with ARDS caused by miliary TB were divided into survivor group (n = 45) and non-survivor group (n = 40).

Our research protocol was approved by the institutional review boards of all participating institutions.

Data collection
The original case records including clinical profiles and laboratory parameters at admission were gathered from the registration departments. Age, sex, past medical history, underlying diseases, PaO2/FiO2, time from admission to anti-tuberculosis therapy, duration of time to diagnosis, and lengths of stay in the ICU and in the hospital were collected. Acute Physiology and Chronic Health Evaluation (APACHE) III score were calculated on the day of diagnosis with ARDS. The results of acid-fast bacilli(AFB) smears, culture of respiratory specimens including sputum, tracheal aspirate or bronchoalveolar lavage (BAL) fluid and histopathological examination were recorded. Laboratory data including aspartate aminotransferase (AST), alanine aminotransferase (ALT), erythrocyte sedimentation rate (ESR), D-dimer, hemoglobin, and albumin was taken during the first 24 h of admission.

Definition
The diagnosis of miliary TB was made based on: equality of the size, distribution, density miliary-like nodules bilaterally diffused on chest radiography by at least 2 independent of radiologists. Pulmonary TB was confirmed by at least one of the three following criteria:1) positive AFB smear and/or culture for M. tuberculosis from respiratory specimens; 2) histopathological identification of TB granuloma in biopsied tissues of lung, and/or pleura; 3) clinical and radiographic improvement after anti-tuberculosis treatment[4]. The diagnosis of ARDS was made in accordance to the diagnostic criteria of European-American Consensus Conference on ARDS[12]: acute in onset with PaO2/FiO2 ≤ 200mmHg, bilateral infiltrates seen on chest radiograph, and pulmonary artery wedge pressure ≤ 18 mm Hg. Survivors were defined as patients who survived to discharge from hospital. Patients with human immunodeficiency virus (HIV), H1N1 Influenza A, and procalcitonin (PCT) positive were excluded.

Statistical analysis
Continuous variables were presented as mean ± standard deviation (SD) or median and compared using an unpaired t-test and the Mann–Whitney U test. Categorical variables were compared using the Chi-squared test. Multivariate logistic regression analysis was performed to determine the predictors. All statistical analysis were performed using SPSS 13.0. P < 0.05 was considered significant.

Results
Patient characteristics
Patients’ clinical characteristics and outcome are presented in Table 1. All patients experience typical symptoms of miliary TB. Diabetes mellitus (DM) was the most common underlying disease (18.8%). Thirty-three (38.8%) patients had been initially misdiagnosed with viral pneumonia, hypersensitivity pneumonitis, acute interstitial pneumonia, fungal pneumonia, alveolar cell carcinoma, or meningitis for a median of 7.2 ± 3.4 days from admission. The diagnosis of miliary TB was established by AFB smear and/or culture of respiratory specimens (including sputum, tracheal aspirate or BAL fluid) in 61 patients (71.8%), by histopathological examination of tissue biopsy in 11 patients (12.9%), and by clinicoradiological diagnosis in 13 patients (15.3%). Bacterial isolate drug sensitivity data were available from 43 patients (50.6%), 3 (3.5%) demonstrated at least single drug resistance.

Hospital course and outcome
The time from admission to anti-tuberculosis therapy was 4.5 ± 2.0 days. All 85 patients with ARDS were prescribed anti-tuberculosis medication consisting of isoniazid, rifampicin, ethambutol, and pyrazinamide. Mechanical ventilation was necessary in all 85 patients. Thirty-eight patients (44.7%) required invasive mechanical ventilation while the rest were given non-invasive mechanical ventilation with BiPAP. Mean duration of mechanical ventilation was 8.5 ± 3.0 days with ICU mortality of 47.1%. Thirty-five patients (41.2%) received glucocorticoid
therapy (methylprednisolone:80 mg/day) intravenously for a maximum of 5 days when anti-tuberculosis therapy was started. The use of glucocorticoids was associated with a mortality of 22.9% (8/35) compared with 76.0% (38/50) in those who were not treated with glucocorticoids.

Comparison between patients with miliary TB developing ARDS and patients with miliary TB alone are shown in Table 2. Comparison between survivors and non-survivors of ARDS patients are shown in Table 3. Duration of time to diagnosis, time from diagnosis to mechanical ventilation, and time from admission to anti-tuberculosis therapy were significantly shorter in survivors than non-survivors. Also, DM, ALT, AST, D-dimer, hemoglobin, and albumin showed significant difference between the survivor group and non-survivor group. The 3 pregnant patients underwent termination of pregnancy, one of whom died of respiratory failure.

Predictors of ARDS development caused by military TB
Positive likelihood ratio were performed to analyze sensitivity and specificity of the predictors level (the greater the ratio the greater probability of true positive in a positive result) (Table 4). On multivariate logistic regression analysis, presence of DM(OR 5.431, 95%CI 1.471-20.049; P = 0.005), ALT (70-100U/L, OR 10.029, 95%CI 2.764-36.389; P = 0.001), AST (>94U/L, OR 8.034, 95%CI 2.200-29.341; P = 0.002), D-dimer (>1.6mg/L, OR 3.167, 95%CI 0.896-11.187; P = 0.042), hemoglobin (<90g/L, OR 14.824, 95%CI 3.713-59.179; P = 0.001), albumin (<25g/L, OR 15.896, 95%CI 3.975-63.566; P = 0.001)

Table 1 Clinical characteristics, investigations and outcome of patients with ARDS caused by miliary TB (n = 85)

| Parameters                              | Results       |
|-----------------------------------------|---------------|
| Age (years)                             | 36.6 ± 12.5   |
| Sex (male)                              | 38(44.7%)     |
| Clinical findings                       |               |
| Fever, cough, dyspnoea, weight loss     | 85 (100)      |
| Diabetes mellitus                       | 16 (18.8)     |
| Past history of tuberculosis            | 9(10.6)       |
| Hepatitis B                             | 8 (9.4)       |
| Pregnancy                               | 3 (3.5)       |
| Heart disease                           | 3(3.5)        |
| Cerebrovascular disease                 | 2(2.3)        |
| Investigations                          |               |
| APACHE III score                        | 71.6 ± 21.9   |
| PaO2/FIO2(mmHg)                         | 146.4 ± 34.5  |
| Outcome                                 |               |
| Duration of symptoms (days)             | 16.1 ± 5.2    |
| Misdiagnosis for other diseases         | 33 (38.8)     |
| Time to diagnosis (days)                | 7.2 ± 3.4     |
| Length of stay in the ICU(days)         | 15.3 ± 3.5    |
| Length of stay in the hospital(days)    | 26.7 ± 4.6    |
| Duration of mechanical ventilation (days)| 8.5 ± 3.0    |
| Time from admission to anti-tuberculosis therapy (days) | 4.5 ± 2.0 |
| Glucocorticoids therapy                 | 35 (41.2)     |
| ICU mortality                           | 40(47.1)      |

Data are presented as mean ± SD or n(%).

Table 2 Comparisons of demographic parameters, clinical and laboratory characteristics between ARDS group and non-ARDS group

| Parameters                              | ARDS(n = 85) | non-ARDS(n = 381) | P-value |
|-----------------------------------------|--------------|-------------------|---------|
| Age(years)                              | 36.6 ± 12.5  | 38.1 ± 11.9       | 0.892   |
| Sex(male)                               | 38(44.7%)    | 113(40.2%)        | 0.710   |
| ALT (U/L)                               | 73.7 ± 20.9  | 30.9 ± 25.8       | 0.001   |
| AST (U/L)                               | 94.8 ± 18.2  | 35.7 ± 23.1       | 0.001   |
| ESR(mm/the first hour)                  | 40.3 ± 18.8  | 42.8 ± 28.6       | 0.653   |
| D-dimer (g/L)                           | 1.2 ± 0.5    | 0.3 ± 0.2         | 0.001   |
| Hemoglobin (g/L)                        | 83.5 ± 16.2  | 125.4 ± 35.4      | 0.011   |
| Albumin (g/L)                           | 29.3 ± 3.7   | 40.2 ± 14.1       | 0.001   |

Data are presented as mean ± SD or n (%). AST: aspartate aminotransferase; ALT: alanine aminotransferase. ESR: erythrocyte sedimentation rate.

Table 3 Comparisons of demographic parameters, clinical and laboratory characteristics between survivors and non-survivors of ARDS patients

| Parameters                              | Survivors (n = 45) | Non-survivors (n = 40) | P-value |
|-----------------------------------------|--------------------|------------------------|---------|
| Age(years)                              | 35.8 ± 9.5         | 37.1 ± 14.2            | 0.899   |
| Sex(male)                               | 20(44.4)           | 18(45)                 | 0.745   |
| DM                                      | 4(8.89)            | 12(30)                 | 0.017   |
| APACHE III score                        | 704 ± 23.6         | 728 ± 19.1             | 0.856   |
| PaO2/FIO2(mmHg)                         | 1490.5 ± 37.8      | 1437 ± 31.9            | 0.648   |
| Time to diagnosis (days)                | 3.2 ± 2.7          | 11.8 ± 4.1             | 0.002   |
| Time from admission to anti-tuberculosis therapy (days) | 2.5 ± 3.4       | 8.6 ± 5.3              | 0.034   |
| Length of stay in the ICU(days)         | 19.3 ± 4.9         | 12.4 ± 3.2             | 0.267   |
| Length of stay in the hospital(days)    | 294 ± 5.6          | 173 ± 4.2              | 0.366   |
| ALT (U/L)                               | 56.2 ± 19.6        | 93.2 ± 22.4            | 0.038   |
| AST (U/L)                               | 63.8 ± 18.1        | 118.2 ± 21.4           | 0.019   |
| ESR(mm/the first hour)                  | 400.1 ± 18.1       | 406.6 ± 18.9           | 0.714   |
| D-dimer (g/L)                           | 0.6 ± 0.8          | 1.8 ± 0.6              | 0.017   |
| Hemoglobin (g/L)                        | 92.7 ± 14.8        | 76.2 ± 20.9            | 0.032   |
| Albumin (g/L)                           | 346.3 ± 3.9        | 239.3 ± 3.2            | 0.027   |

Data are presented as mean ± SD or n(%).
were independent predictors of ARDS development caused by military TB.

**Discussion**

In the present study, our results demonstrated accurate diagnosis and early therapeutic management were crucial to optimizing outcome and DM, ALT, AST, D-dimer, hemoglobin, and albumin are independent predictors of ARDS development in patients with miliary TB. Tuberculosis remains a major cause of morbidity and mortality around the world, especially in developing countries [13,14]. According to the 13th annual tuberculosis report of the World Health Organization (WHO), there were an estimated 9.27 million new cases worldwide in 2007, an increase from 9.24 million in 2006[1]. Further, miliary TB is an uncommon cause of ARDS with a high mortality [4,15]. The current study was performed in Chongqing, the fourth central municipality of China, which has a prevalence rate of 0.54%, higher than the national average. In our study, the average age of patients with ARDS caused by miliary TB was younger than that previously reported due to the possible reason of host factors including region, race, and environment [3,4].

Mechanical ventilation is an important treatment for miliary TB complicated by ARDS. Prompt mechanical ventilation from the day of diagnosis can effectively improve outcome, which benefits for the management of ARDS caused by miliary TB. Also, accurate diagnosis and early anti-tuberculosis therapy are crucial to the treatment of miliary TB with ARDS. However, the high overall mortality is attributed to case mix, misdiagnosis, and severity of illness, which ultimately lead to the delay in the initiation of anti-tuberculosis therapy or mechanical ventilation.

Albumin plays an important role in regulating plasma osmolality. Hypoproteinemia accelerates fluid exudation, promotes alveolar edema, and contributes to ventilation-perfusion imbalance. Also, in infected mycobacterium tuberculosis, inflammatory cells accumulate in the alveolar spaces, releasing granular enzymes and oxidants which participate in local inflammation and overlapping reactions and damaging the alveolar basement which allows increase in cellular permeability that aggravates oxygen dysfunction and consequently causes ARDS [16,17]. If the process continues, cytokines activate an inflammatory cascade reaction and lead to other organs dysfunction, resulting in increases in AST and ALT. The changes in AST, ALT, and serum albumin were significantly different between survivor and non-survivor groups. The results showed that AST, ALT, and serum albumin could be independent predictors of ARDS development in miliary TB.

**Table 4 The levels of predictors for ARDS development caused by military TB**

| Predicators | Sensitivity | Specificity | Positive likelihood ratio |
|-------------|-------------|-------------|--------------------------|
| ALT         |             |             |                          |
| Level 1     | 41.9%       | 4.8%        | 0.44                     |
| Level 2     | 19.4%       | 96.3%       | 5.24                     |
| Level 3     | 25.8%       | 99.7%       | 86.00                    |
| Level 4     | 12.9%       | 99.1%       | 14.33                    |
| AST         |             |             |                          |
| Level 1     | 32.2%       | 8.5%        | 0.35                     |
| Level 2     | 22.6%       | 96.0%       | 5.65                     |
| Level 3     | 29.0%       | 96.0%       | 7.25                     |
| Level 4     | 16.1%       | 99.4%       | 26.83                    |
| D-dimer     |             |             |                          |
| Level 1     | 64.5%       | 23.7%       | 0.84                     |
| Level 2     | 25.8%       | 76.8%       | 1.11                     |
| Level 3     | 3.2%        | 99.4%       | 5.33                     |
| Level 4     | 6.5%        | 100%        | +∞                       |
| Hemoglobin  |             |             |                          |
| Level 1     | 22.6%       | 8.2%        | 0.25                     |
| Level 2     | 19.4%       | 93.5%       | 2.98                     |
| Level 3     | 22.6%       | 98.9%       | 20.55                    |
| Level 4     | 35.5%       | 99.4%       | 59.16                    |
| Albumin     |             |             |                          |
| Level 1     | 16.1%       | 5.6%        | 0.17                     |
| Level 2     | 58.1%       | 96.3%       | 15.70                    |
| Level 3     | 12.9%       | 98.6%       | 9.21                     |
| Level 4     | 12.9%       | 99.4%       | 21.50                    |

ALT: Level 1: 0-40 U/L; Level 2: 40-70 U/L; Level 3: 70-100 U/L; Level 4: > 100 U/L.
AST: Level 1: < 34 U/L; Level 2: 34-64 U/L; Level 3: 64-94 U/L; Level 4: > 94 U/L.
D-dimer: Level 1: 0.34 mg/L; Level 2: 0.34-1.0 mg/L; Level 3: 1.0-1.6 mg/L; Level 4: > 1.6 mg/L.
Hemoglobin: Level 1: 110-160 g/L; Level 2: 100-110 g/L; Level 3: 90-100 g/L; Level 4: < 90 g/L.
Albumin: Level 1: 35-50 g/L; Level 2: 30-35 g/L; Level 3: 25-30 g/L; Level 4: < 25 g/L.
Hyperglycemia is known to have a proinflammatory effect, and may be correlated with poor outcome in hospitalized/critically ill patients. Consistent with this correlation, odds ratio analysis after ARDS development identified DM as a risk factor.

To further understand the accurate levels of the predictors for predicting ARDS, we used stratified analysis for each index. Positive likelihood ratio was included in the study due to a combination of sensitivity and specificity to reflect the reality of the indicators. ALT (>70-100U/L), AST (>94U/L), D-dimer (>1.6mg/L), hemoglobin (<90g/L), and albumin (<25g/L) at the time of admission were independent predictors for ARDS development in the setting of miliary TB. Simple miliary TB can damage organs, inducing mild increases in ALT and AST, although these incremental changes are too small to have any accuracy in predicting the occurrence of ARDS. However, when one develops ARDS, inflammatory mediators will seriously damage the organs, resulting in significantly higher increases in the indexes than those in simple miliary TB, which may translate into higher accuracy for predicting ARDS. Though ESR was significantly elevated in miliary TB, it did not reach statistical significance in association with ARDS. Our findings suggested that ESR has minimal value in predicting ARDS.

In addition, for patients with miliary TB who developed ARDS during pregnancy, there are few case reports with favorable outcome. Our data suggested that pregnancy was a risk factor for ARDS, but this clinical observation was limited by the small sample size. The efficacy of systemic corticosteroids is well-documented for several extrapulmonary complications of tuberculosis such as tuberculous meningitis and tuberculous pericarditis [24-28], as well as ARDS[29-32]. The role of glucocorticoids remains controversial in the management of miliary TB complicated by ARDS[33,34]. In our study, patients treated with glucocorticoids had a lower mortality than those who did not, which might suggest that methylprednisolone at a dose of 80 mg/day was given intravenously at the time when anti-tuberculosis therapy was started might be benefit for ARDS associated with miliary TB. The limitations of this study are studies with large numbers of patients may be required to validate the observations due to a relatively small sample size in the present study.

Conclusions
In conclusion, the mortality of ARDS caused by miliary TB remains high. Accurate diagnosis and early therapeutic management of therapy including anti-tuberculosis agents and mechanical ventilation are crucial to optimizing outcome. DM, ALT, AST, D-dimer, hemoglobin, and albumin are independent predictors of ARDS development in patients with miliary TB.

Competing interests
The authors declare that they have no competing interests.

Acknowledgement
This study was supported by a grant from the National Natural Science Foundation of China (Approval No. 30971303).

Author details
1Department of Respiratory Medicine, Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. 2Department of Medicine, New York University Langone Medical Center, New York, USA. 3Department of Respiratory Medicine, First Affiliated Hospital of Chongqing Medical University, Chongqing, China. 4Department of Respiratory Medicine, Chongqing Chest Hospital, Chongqing, China. 5Department of Respiratory Medicine, Chongqing Pulmonary Hospital, Chongqing, China.

Authors’ contributions
WD, HM and DXW participated in the conception and design of the study. WD, MY, LAH, GC, YW, JD, CYL and JT performed the acquisition of data and the statistical analysis. WD drafted the manuscript. MY helped to draft the manuscript and coordination. HM and DXW participated in the revision of the manuscript. All authors have read and approved the final manuscript.

Received: 16 September 2011 Accepted: 20 May 2012
Published: 20 May 2012

References
1. Donalé PR, van Helden PD: The global burden of tuberculosis–combating drug resistance in difficult times. N Engl J Med. 2009, 360:2393–2395.
2. Sharma P, Jain S, Bameza R, Tiwari P: Increased prevalence of pulmonary tuberculosis in male adults of sahariya tribe of India: a revised survey. Indian J Community Med. 2010, 35:267–271.
3. Agarwal R, Gupta D, Aggarwal AN, Behera D, Jindal SK: Experience with ARDS caused by tuberculosis in a respiratory intensive care unit. Intensive Care Med. 2005, 31:1284–1287.
4. Kim YJ, Park YB, Kim YS, Kang SB, Shin JW, Park IW, Choi BW: Miliary tuberculosis and acute respiratory distress syndrome. Int J Tuberc Lung Dis. 2003, 7:355–364.
5. Sharma SK, Mohan A, Banga A, Saha PK, Guntupalli KK: Predictors of development and outcome in patients with acute respiratory distress syndrome due to tuberculosis. Int J Tuberc Lung Dis. 2006, 10:429–435.
6. Kim YJ, Park CM, Jeong E, Na JO, Oh YM, Lee SD, Kim WS, Kim DS, Kim WD, Shin TS: Pulmonary tuberculosis with acute respiratory failure. Eur Respir J. 2008, 32:1625–1630.
7. Heap MJ, JBlon JF, Hunter KR: Miliary tuberculosis and the adult respiratory distress syndrome. Respir Med. 1989, 83:153–156.
8. Mohdaj A, Gulfrin JM, Kidooshe R, Massmoudi R, Madye Y: Acute respiratory distress syndrome and panniculopathy during miliary tuberculosis in a HIV positive patient. Ann Fr Anesth Reanim. 1996, 15:1203–1206.
9. Piqueras AR, Maruecos L, Artigas A, Rodriguez C: Miliary tuberculosis and adult respiratory distress syndrome. Intensive Care Med. 1987, 13:175–182.
10. Banga A, Mohan A, Saha PK, Sharma SK: Predictors of Development of Acute Respiratory Distress Syndrome in Miliary Tuberculosis. Chest. 2004, 126(Suppl):753.
11. Homan W, Harman E, Braun NM, Felton CP, King TK, Smith JP: Miliary tuberculosis presenting as acute respiratory failure: treatment by membrane oxygenator and ventilator pump. Chest. 1975, 67:366–369.
12. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, Legall JR, Morris A, Spragg R: The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994, 149:818–824.
13. Tsang KW, File TM Jr: Respiratory infections unique to Asia. Respirology. 2008, 13:937–949.
14. Kurata K, Kabuyori T, Shimizu K, Kubota M, Hamaguchi R, Wakaki M, Goto T, Onaka A, Kato R, Oymada Y: Usefulness of serum procalcin measurement in the diagnosis of respiratory infectious disease. Nihon Kokyuki Gakkai Zasshi. 2010, 48:654–660.
15. Mohan A, Sharma SK, Pandey JN: Acute respiratory distress syndrome (ARDS) in miliary tuberculosis: a twelve-year experience. Indian J Chest Dis Allied Sci. 1996, 38:157–162.
16. Perez RL, Rivera-Marrero CA, Roman J: Pulmonary granulomatous inflammation: From sarcoidosis to tuberculosis. Semin Respir Infect 2003, 18:23–32.

17. Matuschak GM, Lechner AJ: Acute lung injury and the acute respiratory distress syndrome: pathophysiology and treatment. Mo Med 2010, 107:252–258.

18. Baynes RD, Flax H, Bothwell TH, Bezwoza WR, MacPhail AP, Atkinson P, Lewis D: Haematological and iron-related measurements in active pulmonary tuberculosis. Scand J Haematol 1986, 36:280–287.

19. Morris CD, Bird AR, Nell H: The haematological and biochemical changes in severe pulmonary tuberculosis. Q J Med 1989, 73:1151–1159.

20. Cameron SJ, Horne NW: The effect of tuberculosis and its treatment on erythropoiesis and folate activity. Tuber 1971, 52:37–48.

21. Weiss G: Pathogenesis and treatment of anaemia of chronic disease. Blood Rev 2002, 16:87–96.

22. Means RT Jr: Recent developments in the anemia of chronic disease. Curr Hematol Rep 2003, 2:116–121.

23. Weiss G, Goodnough LT: Anemia of chronic disease. N Engl J Med 2005, 352:1011–1023.

24. Erbes R, Oettel K, Raffenberg M, Mauch H, Schmidt-Ioanas M, Lode H: Characteristics and outcome of patients with active pulmonary tuberculosis requiring intensive care. Eur Respir J 2006, 27:1223–1228.

25. Lee PL, Jerng JS, Chang YL, Chen CF, Hsueh PR, Tu CJ, Yang PC, Luh KT: Patient mortality of active pulmonary tuberculosis requiring mechanical ventilation. Eur Respir J 2003, 22:141–147.

26. Wallis RS: Reconsidering adjuvant immunotherapy for tuberculosis. Clin Infect Dis 2005, 41:201–208.

27. Thwaites GE, Nguyen DB, Nguyen HD, Hoang TQ, Do TT, Nguyen TC, Nguyen QT, Nguyen TT, Nguyen NH, Nguyen TN, Nguyen NL, Nguyen HD, Vu NT, Cao HH, Tran TH, Pham PM, Nguyen TD, Stepniowska K, White NJ, Tran TH, Farrar JJ: Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 2004, 351:1741–1751.

28. Strang JI, Kakaza HH, Gibson DG, Girling DJ, Nunn AJ, Fox W: Controlled trial of prednisolone as adjuvant in treatment of tuberculous constrictive pericarditis in Transkei. Lancet 1987, 2:1418–1422.

29. Thompson BT: Corticosteroids for ARDS. Minerva Anestesiol 2010, 76:441–447.

30. Meduri GU, Rocco PR, Annane D, Sinclair SE: Prolonged glucocorticoid treatment and secondary prevention in acute respiratory distress syndrome. Expert Rev Respir Med 2010, 4:201–210.

31. Sessler CN, Gay PC: Are corticosteroids useful in late-stage acute respiratory distress syndrome? Respir Care 2010, 55:43–55.

32. Tang BM, Coag XC, Edrick GD, Seppelt J, McLean AS: Use of corticosteroids in acute lung injury and acute respiratory distress syndrome: a systematic review and meta-analysis. Crit Care Med 2009, 37:1594–1503.

33. Sun TN, Yang JY, Zheng LY, Deng WW, Su ZY: Chemotherapy and its combination with corticosteroids in acute miliary tuberculosis in adolescents and adults: analysis of 53 cases. Chin Med J (Engl) 1981, 94:309–314.

34. Massaro D, Katz S, Sachs M: Choroidal tubercles: A clue to hematogenous tuberculosis. Ann Intern Med 1964, 60:231–241.

doi:10.1186/1471-2334-12-121

Cite this article as: Deng et al.: Predictors and outcome of patients with acute respiratory distress syndrome caused by miliary tuberculosis: a retrospective study in Chongqing, China. BMC Infectious Diseases 2012 12:121.